Literature DB >> 12856167

Tumor imaging protocols: problems and challenges.

Mervyn D Cohen1.   

Abstract

Mesh:

Year:  2003        PMID: 12856167     DOI: 10.1007/s00247-003-0979-5

Source DB:  PubMed          Journal:  Pediatr Radiol        ISSN: 0301-0449


× No keyword cloud information.
  10 in total

1.  A methodologic overview of the evaluation of costs and benefits in diagnostic radiology.

Authors:  C J Zylak; A Gafni
Journal:  Invest Radiol       Date:  1992-06       Impact factor: 6.016

Review 2.  Diagnostic imaging in cancer care. The role of cost/benefit analysis.

Authors:  R G Evens
Journal:  Cancer       Date:  1991-02-15       Impact factor: 6.860

Review 3.  Screening for Wilms' tumor in children with high-risk congenital syndromes: considerations for an intervention trial.

Authors:  M R DeBaun; M Brown; L Kessler
Journal:  Med Pediatr Oncol       Date:  1996-11

4.  A rational approach to the radiologic evaluation of children with Wilms' tumor.

Authors:  M D Cohen; A Siddiqui; R Weetman; R Baehner; T Weber; J L Grosfeld
Journal:  Cancer       Date:  1982-09-01       Impact factor: 6.860

5.  Wilms tumor imaging: patient costs and protocol compliance.

Authors:  C W Carrico; M D Cohen; J M Zerin; R Weetman
Journal:  Radiology       Date:  1997-09       Impact factor: 11.105

6.  Position paper: imaging methods for primary renal tumors of childhood: costs versus benefits.

Authors:  G J D'Angio; H Rosenberg; K Sharples; P Kelalis; N Breslow; D M Green
Journal:  Med Pediatr Oncol       Date:  1993

7.  Improved survival for childhood acute lymphoblastic leukemia: possible effect of protocol compliance.

Authors:  O B Eden; C A Stiller; M P Gerrard
Journal:  Pediatr Hematol Oncol       Date:  1988       Impact factor: 1.969

Review 8.  Imaging patients with Wilms tumor.

Authors:  P Babyn; C Owens; M Gyepes; G J D'Angio
Journal:  Hematol Oncol Clin North Am       Date:  1995-12       Impact factor: 3.722

9.  The design and conduct of clinical trials in childhood brain tumors.

Authors:  J C Allen
Journal:  Cancer       Date:  1985-10-01       Impact factor: 6.860

10.  Systems of protocol review, quality assurance, and data audit.

Authors:  R B Weiss
Journal:  Cancer Chemother Pharmacol       Date:  1998       Impact factor: 3.333

  10 in total
  1 in total

1.  [Nephrogenic tumors].

Authors:  P Wiesbauer
Journal:  Radiologe       Date:  2008-10       Impact factor: 0.635

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.